• Home
  • About
    • Psychedelic For Healthy People
    • Psilocybin (Magic Mushrooms)
    • Ayahuasca (Chacruna – Kaapi – Yajé)
    • MDMA (MDA – Sassafras)
    • Peyote Mescaline (Huachuma)
    • Kambo – Amazonian Frog
    • 5-MeO-DMT (Toad Medicine)
    • Rapé And Sacred Tobacco
    • Iboga (Ibogaine)
    • LSD (Lysergic Acid Diethylamide)
    • Cannabis (Marijuana)
    • Ketamine
    • Psychedelic Integration
    • Psychedelics Advocates
    • Frequently Asked Questions
    • Mental Health Symptoms
    • Substances Test Kits
    • Manifesto
  • Treatments
    • Latest Psychedelic Research
    • Addiction
    • Alcoholism
    • Anxiety
    • Bipolar Disorder
    • Cancer
    • Cluster Headaches
    • Depression
    • End Of Life
    • OCD
    • Neuropathy
    • Pain
    • Parkinson’s Disease
    • PTSD
    • Smoking
    • Help Treat Mental Illness
  • Microdosing
    • What is Microdosing?
    • Microdosing Magic Mushrooms
    • Microdosing LSD
    • Microdosing MDMA
    • Microdosing Ayahuasca
    • Microdosing Mescaline
    • Microdosing Cannabis
    • Microdosing Ibogaine
  • Resources
    • Past Events
    • ALL Locations
    • DMT Psychoactive Plants
    • Medical Trials And Research
    • Psychedelic Research
    • EntheoPodcasts
    • In The News
    • Books On Psychedelics
    • Related Videos
    • EntheoResources
    • Terence McKenna
    • What Is Psychedelic Art?
    • Useful Links
    • Movies & Documentaries
    • Michael Pollan
Contact
  • Follow
  • Follow
  • Follow
  • Follow

Unique magic mushroom microdosing study to begin in Australia

by EmpathiCSubstanceS | Apr 25, 2021 | Microdosing

A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics. The research promises to be the first exploration of naturalistic psilocybin microdosing in a lab-setting using a cutting-edge neuroimaging...

Cannabis use linked to more rebound headaches in migraine sufferers

by EmpathiCSubstanceS | Apr 25, 2021 | Addiction, Cannabis Marijuana

New research from scientists at Stanford University School of Medicine suggests cannabis use can be linked to higher rates of “rebound headaches” in migraine sufferers. The research is observational and retrospective, but it is yet another...

Clinical trial finds CBD does not help cocaine addicts kick the habit

by EmpathiCSubstanceS | Apr 25, 2021 | Addiction, Cannabis Marijuana

Cannabidiol, better known as CBD, is rapidly gaining popularity as a potion to treat almost every kind of medical concern you can think of, but scientific evidence is scant outside of a few clinically proven indications. A new study from a team of Canadian researchers...

California bill proposes lawful use and sharing of psychedelic drugs

by EmpathiCSubstanceS | Apr 25, 2021 | Addiction, Cannabis Marijuana

A broad drug reform bill has been introduced to the California state legislature proposing to decriminalize the possession and personal use of a number of psychedelic drugs, including LSD, psilocybin and MDMA. The bill proposes to expunge all criminal convictions...

MDMA proves a promising alcoholism treatment in world-first trial

by EmpathiCSubstanceS | Apr 25, 2021 | Addiction, Alcoholism

A new study published in the Journal of Psychopharmacology is reporting on a landmark clinical trial exploring the potential for MDMA-assisted psychotherapy in treating subjects with alcohol use disorder. The small open-label trial is the first to test MDMA therapy as...
« Older Entries
Next Entries »

IMPORTANT NOTICE:

This community is being designed as a secure space. It is not a place to seek, encourage, or participate in the procurement of controlled substances. Do not bring, buy, sell, transfer, or arrive on any illegal substances, or swap information on how to buy them. Attendees and/or members of this community who violate these basic house rules will be removed from the community and will not be allowed to attend future events.

Psychedelic Research

Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study

Aug 11, 2022

Psilocybin's acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose session...

Potential Psychiatric Uses for MDMA

Aug 11, 2022

In MDMA studies, participants report improved self‐knowledge, sleep regulation, accuracy in perceiving mental states of others, coping strategies, emotion regulation, and cognitive insights. Objective measures support attenuated impact of social rejection and reduced...

The cognitive effects of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) are associated with improvements in depression and anxiety conditions

Aug 11, 2022

Of those reporting a history of being diagnosed with depression (n=149; 41%) or anxiety (n=173; 48%), most reported symptoms were improved (depression=81%; anxiety=79%) following 5-MeO-DMT use and relatively fewer reported symptoms remained the same (depression=17%;...

Psychedelic Medicine

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

© 2025| All Rights Reserved, EntheoMedicine Community
  • Follow
  • Follow
  • Follow
  • Follow